prtga Antibody

What is PRTG protein and why is it significant in research?

PRTG (protogenin) is a membrane-localized protein belonging to the DCC (Deleted in Colorectal Carcinoma) protein family with a molecular mass of approximately 127.1 kDa and comprising 1150 amino acid residues in its canonical human form . The protein plays a critical role in anteroposterior axis elongation during embryonic development, making it an important target for developmental biology research . PRTG has several synonyms in scientific literature, including "protogenin homolog (Gallus gallus)," "shen-dan," and "immunoglobulin superfamily, DCC subclass, member 5," which researchers should be aware of when reviewing literature . Its conservation across multiple species including mouse, rat, bovine, frog, zebrafish, chimpanzee, and chicken further highlights its biological significance and enables comparative studies across model organisms . Additionally, PRTG serves as a marker for Gray Matter MGE Interneurons, making PRTG antibodies valuable tools for researchers studying neuronal differentiation and brain development .

What are the common applications of PRTG antibodies in research?

PRTG antibodies are employed in multiple experimental techniques across various research contexts. Immunofluorescence (IF) represents one of the most widely used applications, enabling researchers to visualize PRTG expression patterns within tissue samples and cultured cells to determine subcellular localization patterns and co-localization with other proteins of interest . Western blot (WB) applications allow researchers to confirm PRTG protein expression levels, verify antibody specificity, and monitor changes in PRTG expression under various experimental conditions or across developmental stages . Immunocytochemistry (ICC) represents another common application, permitting detailed analysis of PRTG expression in cultured cells, with the potential to combine with functional assays to correlate protein expression with cellular behaviors . Immunohistochemistry-paraffin (IHC-p) techniques enable researchers to detect PRTG in fixed tissue sections, allowing for spatiotemporal expression analysis in developmental studies and pathological specimens . For optimal experimental outcomes, researchers should validate antibodies for their specific application, as antibody performance can vary significantly between applications even when using the same PRTG antibody product.

How do I select the appropriate PRTG antibody for my specific research application?

Selecting the optimal PRTG antibody requires careful consideration of multiple factors tailored to your experimental design. First, determine the specific application requirements (Western blot, immunofluorescence, immunohistochemistry), as certain antibodies perform better in particular applications - for example, some PRTG antibodies are specifically validated for IHC-p while others excel in WB and IF applications . Consider the species reactivity requirements for your research; available PRTG antibodies demonstrate reactivity with human samples, while others offer cross-reactivity with mouse, rat, or other species, which is crucial for comparative studies or when using animal models . Evaluate antibody format preferences, choosing between monoclonal antibodies (offering high specificity and reproducibility) and polyclonal antibodies (providing broader epitope recognition), based on your experimental needs . For specialized applications, consider whether conjugated antibodies (fluorophore-labeled or enzyme-linked) might streamline your workflow by eliminating secondary antibody steps . Additionally, review literature utilizing PRTG antibodies in similar research contexts and examine supplier validation data, including images and protocols demonstrating antibody performance in applications similar to yours, before making a final selection.

What controls should I include when using PRTG antibodies in immunoassays?

Implementing appropriate controls when using PRTG antibodies is essential for experimental rigor and result validation. Always include a positive control consisting of a sample known to express PRTG, such as developing neural tissues or cell lines with confirmed PRTG expression, to verify antibody functionality and establish expected staining patterns . Incorporate a negative control by using samples known not to express PRTG or by using genetic knockdown/knockout models where PRTG has been depleted, allowing you to identify potential non-specific binding . Technical negative controls should include omitting the primary PRTG antibody while maintaining all other steps in the protocol, which helps detect non-specific binding from secondary antibodies or reagents . For more rigorous validation, include a blocking peptide control where the PRTG antibody is pre-incubated with the immunizing peptide before application to samples, which should abolish specific staining if the antibody is truly specific . When performing quantitative analysis, implement appropriate isotype controls (antibodies of the same isotype but irrelevant specificity) to establish background signal levels . For novel research applications or when working with understudied tissues, consider using two different PRTG antibodies recognizing distinct epitopes to confirm specificity through concordant staining patterns.

What is the optimal protocol for using PRTG antibodies in Western blotting?

Western blotting with PRTG antibodies requires careful optimization to detect this 127.1 kDa membrane protein effectively. Begin with sample preparation using a lysis buffer containing appropriate detergents (e.g., 1% Triton X-100 or 0.5% NP-40) and protease inhibitors to efficiently extract and preserve the membrane-localized PRTG protein . For gel electrophoresis, use lower percentage (6-8%) SDS-PAGE gels to ensure proper resolution of the large 127.1 kDa PRTG protein, and consider longer running times to achieve clear band separation from other high molecular weight proteins . During transfer to membranes, implement an extended transfer time (90-120 minutes) or use semi-dry transfer systems optimized for high molecular weight proteins to ensure complete transfer of PRTG . For blocking, use 5% non-fat dry milk or BSA in TBS-T for 1-2 hours at room temperature, followed by overnight incubation with primary PRTG antibody at 4°C using the manufacturer's recommended dilution (typically 1:500 to 1:2000) . After thorough washing with TBS-T (4-5 washes of 5-10 minutes each), incubate with appropriate HRP-conjugated secondary antibody for 1-2 hours at room temperature, followed by additional washing steps . For visualization, use enhanced chemiluminescence detection with longer exposure times if needed, as PRTG may show variable expression levels depending on the tissue or cell type . When interpreting results, account for potential post-translational modifications, particularly glycosylation, which may affect the apparent molecular weight of PRTG on Western blots .

How can I optimize PRTG antibody specificity for detecting closely related family members?

Enhancing PRTG antibody specificity for distinguishing between closely related DCC family members requires advanced techniques and careful experimental design. Implement computational epitope analysis by utilizing bioinformatics tools to compare sequence homology between PRTG and other DCC family members, identifying unique epitope regions specific to PRTG that can be targeted for antibody generation or selection . Consider employing depletion strategies where your samples are pre-incubated with recombinant proteins of closely related family members to sequester antibodies that might cross-react, leaving only PRTG-specific antibodies available for detection . For highly specific detection, custom antibody development targeting unique regions (such as non-conserved segments of the extracellular domain) can be commissioned, with subsequent affinity purification against PRTG-specific peptides to remove antibodies recognizing conserved epitopes . Advanced validation approaches should include parallel testing in knockout/knockdown systems for both PRTG and related family members to comprehensively map cross-reactivity profiles . For critical applications requiring absolute specificity, consider implementing competitive binding assays with labeled and unlabeled antibodies to quantitatively assess binding kinetics and cross-reactivity . Additionally, structure-based antibody design approaches can be employed, utilizing computational modeling of antibody-antigen interactions to predict and engineer enhanced specificity for PRTG over related proteins, followed by experimental validation .

What approaches can resolve contradictory PRTG antibody staining patterns in tissue samples?

Resolving contradictory staining patterns when using PRTG antibodies requires systematic troubleshooting and validation approaches. Begin with epitope mapping analysis by employing multiple PRTG antibodies targeting different epitopes to determine if discrepancies arise from detecting different isoforms, cleavage products, or post-translationally modified versions of PRTG . Implement parallel validation using orthogonal detection methods such as in situ hybridization for PRTG mRNA, which can confirm expression patterns independently of protein detection methods and help distinguish between antibody artifacts and true expression . Conduct comprehensive antibody validation through systematic testing in positive and negative control samples, including tissues from PRTG knockout models or PRTG-overexpressing systems to definitively establish specificity profiles for each antibody . For difficult tissues, optimize fixation and antigen retrieval protocols systematically, as PRTG detection may be particularly sensitive to fixation artifacts due to its complex membrane topology and post-translational modifications like glycosylation . When contradictions persist, implement multiplexed detection combining PRTG antibodies with markers of specific cell types or subcellular compartments to contextualize inconsistent results and potentially explain biological variability . Consider conducting computational binding mode analysis to predict how different antibodies interact with PRTG under various experimental conditions, which can help explain discrepancies and direct optimization efforts .

How can computational approaches enhance PRTG antibody design and validation?

Computational methodologies offer powerful tools for enhancing both the design and validation of PRTG antibodies. Implement biophysics-informed modeling to predict antibody-antigen interactions by training models on experimentally selected antibodies, enabling the identification of distinct binding modes associated with PRTG epitopes and the generation of antibody variants with customized specificity profiles . Utilize structure prediction workflows that incorporate fully guided homology modeling with de novo CDR loop conformation prediction to construct reliable 3D structural models of anti-PRTG antibodies directly from sequence data, facilitating rational design improvements . Apply ensemble protein-protein docking techniques to predict antibody-antigen complex structures and identify favorable antibody-PRTG contacts, allowing researchers to enhance resolution of experimental epitope mapping data from peptide to residue-level detail . For high-throughput approaches, implement batch homology modeling to accelerate model construction for parent sequences and their variants, enabling efficient screening of potential anti-PRTG antibody candidates . Minimize development risks by employing computational tools to identify potential surface sites for post-translational modification and chemical reactivity on antibodies, as well as detecting potential hotspots for aggregation through protein surface analysis . Advanced engineering can be accomplished through in silico methods that accurately predict the impact of residue substitution on binding affinity, selectivity, and thermostability, using techniques such as Residue Scan FEP+ with lambda dynamics and Protein Mutation FEP+ to refine antibody candidate selection .

What are the methodological considerations for using PRTG antibodies in multiplex immunoassays?

Implementing PRTG antibodies in multiplex immunoassays requires careful optimization to ensure specific detection alongside other targets. Begin with a comprehensive cross-reactivity assessment by testing each antibody in the multiplex panel individually and in combination to identify and mitigate any cross-reactivity between antibodies, particularly when multiple rabbit-derived antibodies are used . Optimize signal separation through careful selection of fluorophores or reporter systems with minimal spectral overlap, and when using PRTG antibodies with other antibodies targeting the DCC family, consider sequential staining protocols to prevent epitope competition or steric hindrance . Implement careful antibody titration for each component in the multiplex panel, as optimal concentrations for PRTG antibodies may differ between single-plex and multiplex applications due to buffer effects and antibody interactions . For spatial multiplexing techniques, optimize antigen retrieval conditions that work compatibly for all targets, noting that the membrane-localized nature of PRTG may require different retrieval methods than cytoplasmic or nuclear targets . Consider employing advanced signal amplification methods like tyramide signal amplification or polymer-based detection systems when working with tissues where PRTG expression is low or when multiple rounds of staining are required . For complex multiplex panels, validate the entire workflow using appropriate control tissues with known expression patterns of all targets and implement computational image analysis tools to accurately quantify co-localization and expression levels across multiple channels .

How can I develop custom PRTG antibodies with specific binding profiles for novel applications?

Developing custom PRTG antibodies with tailored binding profiles requires sophisticated approaches combining experimental and computational methods. Begin with epitope selection by conducting bioinformatic analysis of the PRTG sequence to identify regions that are highly conserved across species for broad reactivity, or species-specific segments for selective targeting, while avoiding regions prone to post-translational modifications unless these modifications are specifically of interest . Implement phage display technology to generate a diverse antibody library, and conduct selections against specific combinations of PRTG-containing complexes to identify antibodies with desired specificity profiles, following established protocols for selection and amplification . Integrate high-throughput sequencing and computational analysis to characterize selected antibodies and identify distinct binding modes associated with specific PRTG epitopes, enabling the generation of antibodies with customized specificity beyond those probed experimentally . For structure-based design, utilize computational tools to predict antibody-PRTG interactions, rationally engineer CDR regions, and evaluate the percentage of humanness if developing therapeutic antibodies . Consider hybrid approaches combining traditional immunization methods with rational design, where initial antibodies from immunized animals are sequenced and computationally optimized to enhance desired properties while minimizing unwanted cross-reactivity . Validate developed antibodies through comprehensive testing against PRTG variants, related proteins, and in multiple application contexts, implementing both experimental validation and computational prediction of binding affinities .

How do I troubleshoot weak or absent PRTG antibody signals in immunoassays?

Addressing weak or absent signals when using PRTG antibodies requires systematic evaluation of multiple experimental parameters. First, verify sample integrity by confirming PRTG expression in your samples through RT-PCR or using validated positive control tissues known to express PRTG, as expression can vary significantly across developmental stages and tissue types . Optimize fixation and permeabilization protocols, noting that PRTG's membrane localization may require specific detergent concentrations (0.1-0.3% Triton X-100 or 0.05-0.1% Saponin) to adequately expose epitopes without disrupting membrane architecture . Implement epitope retrieval optimization by testing multiple antigen retrieval methods (heat-induced epitope retrieval with citrate buffer pH 6.0, EDTA buffer pH 9.0, or enzymatic retrieval with proteinase K) to unmask epitopes potentially obscured by fixation or protein interactions . Consider signal amplification techniques such as tyramide signal amplification, polymer-based detection systems, or biotin-streptavidin amplification to enhance detection sensitivity, particularly for tissues with low PRTG expression . Evaluate antibody concentration and incubation conditions by testing a range of antibody dilutions (1:100 to 1:2000) and incubation periods (overnight at 4°C versus 1-3 hours at room temperature) to identify optimal parameters . For detecting glycosylated forms of PRTG, consider enzymatic deglycosylation pretreatment of samples, as extensive glycosylation may mask epitopes and reduce antibody accessibility . If these approaches fail, consider testing alternative PRTG antibodies that target different epitopes, as certain domains may be more accessible than others in specific experimental contexts .

What strategies can address non-specific binding when using PRTG antibodies?

Non-specific binding represents a common challenge when working with PRTG antibodies that can be addressed through multiple optimization strategies. Implement enhanced blocking protocols by testing different blocking agents (5% BSA, 5-10% normal serum matching the host species of the secondary antibody, commercial protein-free blockers) and extended blocking times (2-3 hours at room temperature or overnight at 4°C) to minimize non-specific interactions . Optimize antibody dilution through systematic titration experiments to identify the minimum concentration that yields specific signal with minimal background, typically starting with manufacturer recommendations and testing 2-3 dilutions above and below the suggested range . Include competitive peptide controls where the primary PRTG antibody is pre-incubated with excess immunizing peptide before application to samples, which should eliminate specific binding while non-specific binding persists, helping to distinguish true signal from artifacts . For tissue applications, implement additional washing steps using high-salt TBS-T (0.5M NaCl) or PBS-T with 0.2-0.3% Triton X-100 to disrupt weak, non-specific interactions while preserving specific antibody binding . Consider secondary antibody optimization by testing highly cross-adsorbed secondary antibodies specifically designed to minimize cross-reactivity with endogenous immunoglobulins in your sample species . For particularly problematic samples, implement tissue-specific pretreatment protocols such as blocking endogenous biotin (using avidin-biotin blocking kits), inactivating endogenous peroxidases (using 0.3-3% hydrogen peroxide), or blocking endogenous phosphatases (using levamisole) depending on your detection system .

How can I validate PRTG antibody specificity in my experimental system?

Rigorous validation of PRTG antibody specificity requires multifaceted approaches tailored to your experimental context. Implement genetic validation approaches using PRTG knockdown/knockout models or CRISPR-edited cell lines, where the disappearance of signal in genetically depleted samples provides definitive evidence of antibody specificity . Conduct Western blot validation to confirm that the antibody detects a protein of the expected molecular weight (approximately 127.1 kDa for canonical PRTG), with attention to potential glycosylated forms that may appear at higher molecular weights . Perform immunoprecipitation followed by mass spectrometry to definitively identify the proteins pulled down by the PRTG antibody, providing unambiguous confirmation of target specificity and potentially revealing any cross-reactive proteins . For tissue studies, implement parallel detection using two different PRTG antibodies targeting distinct epitopes, where concordant staining patterns strongly support specificity for the intended target . Consider employing orthogonal techniques such as RNA in situ hybridization or fluorescent reporter constructs to independently confirm expression patterns and correlate with antibody-based detection . For advanced validation, implement heterologous expression systems where PRTG is expressed in cell lines that normally lack the protein, allowing clear demonstration of specific binding to the introduced target . Document all validation data systematically, including positive and negative controls, to establish a robust foundation for interpreting experimental results with the validated PRTG antibody.

How can PRTG antibodies be utilized in studying neural development and differentiation?

PRTG antibodies serve as powerful tools for investigating neural development processes through multiple experimental approaches. Implement developmental expression mapping using PRTG antibodies in conjunction with stage-specific markers to characterize the spatiotemporal expression pattern of PRTG throughout embryonic development, particularly during neural tube formation and anteroposterior axis elongation where PRTG plays key roles . Utilize cell fate tracing approaches by combining PRTG immunolabeling with lineage tracing methods to track the developmental trajectory of PRTG-expressing progenitor cells and determine their ultimate fate in mature neural structures . For studying interneuron development, leverage PRTG's role as a marker for Gray Matter MGE Interneurons to investigate the migration, maturation, and integration of these cells into functional neural circuits . Implement co-localization studies pairing PRTG antibodies with antibodies against other developmentally regulated proteins to elucidate potential interaction networks and signaling pathways operating during neural development . Consider using PRTG antibodies in functional blocking experiments, where application of antibodies targeting the extracellular domain can potentially interfere with PRTG-mediated signaling, allowing investigation of its role in axon guidance and cell migration . For studying neurological disorders, examine PRTG expression in disease models to determine whether aberrant expression correlates with developmental abnormalities, potentially providing insights into the molecular basis of neurodevelopmental disorders .

What approaches can integrate PRTG antibody data with transcriptomic and proteomic analyses?

Integrating PRTG antibody-derived data with broader -omics approaches enables comprehensive mechanistic insights into PRTG function. Implement spatial transcriptomics correlated with PRTG immunohistochemistry by performing PRTG antibody staining on tissue sections adjacent to those used for spatial transcriptomics, allowing correlation of PRTG protein expression with genome-wide expression patterns across tissue microenvironments . Utilize single-cell proteogenomics approaches where PRTG antibody-based cell sorting (FACS or MACS) is used to isolate PRTG-expressing cells for subsequent single-cell RNA sequencing, enabling characterization of transcriptional profiles specifically in PRTG-positive cell populations . For network analysis, combine PRTG co-immunoprecipitation with mass spectrometry (IP-MS) to identify PRTG-interacting proteins, and integrate these data with RNA-seq analysis of PRTG knockdown/knockout models to construct comprehensive interaction networks and signaling pathways . Implement sequential multiplexed immunofluorescence techniques where tissues are iteratively stained, imaged, and stripped using panels including PRTG and proteins identified in proteomic screens to validate interactions in situ . For temporal analyses, consider integrating time-course PRTG antibody studies with matched transcriptomic data to elucidate the temporal relationship between PRTG mRNA expression, protein synthesis, post-translational modifications, and subsequent signaling events . Apply computational integration methods including machine learning approaches to identify patterns and relationships between PRTG protein expression data and transcriptomic/proteomic datasets, potentially revealing novel functions or regulatory mechanisms .

How can PRTG antibodies be utilized in high-content screening applications?

PRTG antibodies can be leveraged in high-content screening platforms to investigate developmental processes and identify modulators of PRTG function. Establish automated immunofluorescence workflows by optimizing PRTG antibody staining protocols for compatibility with high-content imaging systems, including appropriate fixation, permeabilization, and detection methods that maintain signal intensity while reducing background across multi-well formats . Implement multiplexed phenotypic screening combining PRTG antibodies with markers for proliferation (Ki67), apoptosis (cleaved caspase-3), and differentiation (lineage-specific markers) to simultaneously assess multiple cellular responses to experimental perturbations . For drug discovery applications, develop PRTG expression-based screens to identify compounds that modulate PRTG expression or localization, potentially revealing agents that influence neural development or regeneration pathways . Utilize machine learning-based image analysis by training algorithms to recognize specific patterns of PRTG expression and subcellular localization, enabling unbiased classification of cellular phenotypes and quantification of subtle changes in expression patterns . Consider implementing live-cell screening approaches using membrane-impermeable PRTG antibodies targeting extracellular epitopes to monitor surface expression dynamics in living cells without fixation, providing insights into receptor trafficking and turnover . For genetic screens, combine PRTG antibody staining with CRISPR libraries or siRNA arrays to systematically identify genes that regulate PRTG expression, localization, or downstream signaling, potentially uncovering novel components of PRTG-associated pathways .

What are the current approaches for using PRTG antibodies in super-resolution microscopy?

Super-resolution microscopy techniques offer unprecedented insights into PRTG localization and interactions when combined with optimized antibody protocols. Implement stimulated emission depletion (STED) microscopy using PRTG antibodies conjugated to STED-compatible fluorophores (such as STAR635P or Abberior STAR RED) to achieve lateral resolution of 30-80 nm, enabling detailed visualization of PRTG distribution within membrane microdomains that is not possible with conventional microscopy . For single-molecule localization microscopy (STORM/PALM), optimize PRTG antibody labeling using appropriate buffer systems (containing oxygen scavenging systems and thiol compounds) and photoswitchable fluorophores (Alexa Fluor 647 or Cy5) to achieve 10-25 nm resolution for precise mapping of PRTG nanoscale organization and clustering patterns . Utilize expansion microscopy by adapting PRTG antibody protocols to work with sample expansion techniques, which physically enlarge specimens while maintaining relative protein positions, providing an alternative approach to achieving super-resolution (effective 70 nm resolution) with standard confocal microscopy . For multiplexed super-resolution applications, implement DNA-PAINT or Exchange-PAINT techniques using PRTG antibodies conjugated to DNA oligonucleotides, allowing sequential imaging of multiple targets with minimal chromatic aberration and high multiplexing capability . Consider correlative light and electron microscopy (CLEM) approaches where PRTG immunolabeling is combined with electron microscopy techniques, providing both molecular specificity and ultrastructural context for PRTG localization studies . Optimize sample preparation specifically for super-resolution applications, including appropriate fixation protocols (typically 4% PFA with glutaraldehyde) and smaller antibody formats (Fab fragments or nanobodies) to minimize the displacement between epitope and fluorophore, which is critical for accurate localization .

How might next-generation PRTG antibody technologies advance developmental neurobiology research?

Emerging antibody technologies promise to transform PRTG-focused developmental neurobiology research through enhanced specificity and novel applications. Implement site-specific antibody conjugation strategies utilizing engineered cysteines or non-natural amino acids to create homogeneous PRTG antibody conjugates with precisely positioned fluorophores, enabling more quantitative and reproducible imaging with improved signal-to-noise ratios . Explore nanobody and single-domain antibody development against PRTG, which offer smaller size (approximately 15 kDa compared to 150 kDa for conventional antibodies), superior tissue penetration, and reduced distance between epitope and label, potentially revolutionizing super-resolution imaging of PRTG in thick tissues or whole embryos . Consider implementing optogenetic antibody systems where PRTG antibodies are coupled to light-sensitive domains, allowing optical control of PRTG function through light-induced clustering, internalization, or degradation to study its role in neural development with unprecedented spatiotemporal precision . Develop split-antibody complementation systems using PRTG antibodies fragmented into non-functional portions that reconstitute active binding sites only when brought together by specific cellular events, enabling dynamic reporting of PRTG conformational changes or protein-protein interactions . Explore integrating PRTG antibodies with emerging spatial multi-omics technologies that combine protein detection with RNA sequencing or chromatin accessibility mapping within the same tissue section, providing comprehensive molecular characterization of PRTG-expressing cells and their microenvironments . Consider developing activity-dependent PRTG antibody reporting systems that can detect activated versus inactive forms of PRTG, potentially revealing dynamics of signaling cascades during key developmental events like neural differentiation or axon guidance .